Highlights Liquidia Corporation

Equities

LQDA

US53635D2027

Real-time Estimate Cboe BZX Other stock markets 12:15:43 2024-05-22 pm EDT			5-day change	1st Jan Change
13.35 ^USD	+0.75%		+8.06%	+10.39%

May. 15	Transcript : Liquidia Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 05:01 PM
May. 14	Transcript : Liquidia Corporation, Q1 2024 Earnings Call, May 14, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Liquidia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell	Mar. 13	MT
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia	Feb. 21	MT
US FDA Yutrepia Review Delay 'Yet Another Setback' For Liquidia, Wedbush Says	Jan. 25	MT
Liquidia Says Yutrepia Inhalation Powder to Treat Hypertension Still Under Review by US FDA	Jan. 25	MT
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder	Jan. 25	CI
Liquidia Says United Therapeutics Filed for Dismissal of Certain Claims in Patent Infringement Litigation	Jan. 23	MT
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder	Jan. 19	CI
Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD	Jan. 05	CI
Liquidia Shares Jump on US Court Win in Patent Dispute With United Therapeutics	Dec. 20	MT
Liquidia Corporation Receives Notice of Allowance with Respect to Its Patent Application Number 17/233,061	Dec. 12	CI
Liquidia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (LQDA) LIQUIDIA CORPORATION Posts Q3 Revenue $3.7M, vs. Street Est of $4.33M	Nov. 07	MT
FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA? Label	23-09-25	CI
Liquidia to Defend Product Access 'Aggressively' After United Therapeutics Secures New Treprostinil-Related Patent	23-08-21	MT
Liquidia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (LQDA) LIQUIDIA CORPORATION Reports Q2 Revenue $4.8M, vs. Street Est of $4.2M	23-08-10	MT
Liquidia Files Amendment With US FDA to Add Indication for Yutrepia	23-07-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Liquidia Corporation

Equities

LQDA

US53635D2027

Highlights

Filters